Moximed

Executive Summary

Moximed is a private medical device company developing the MISHA Knee System, an implantable shock absorber designed to unload the medial knee compartment in patients with medial knee osteoarthritis (OA). The device targets a large unmet need: patients who have failed conservative therapy but are not yet ready for total knee arthroplasty (TKA). By offering a minimally invasive alternative that delays TKA, Moximed addresses a growing market driven by an aging population and rising OA prevalence. The MISHA system has received CE mark in Europe and is under FDA review in the United States following a pivotal clinical trial. The company is well-positioned to capture a niche between early OA management and end-stage joint replacement, with the potential to transform the standard of care for moderate knee OA. Key milestones include completion of enrollment in the U.S. pivotal trial and ongoing long-term follow-up. The company is actively engaging with payers to secure reimbursement and build commercial infrastructure in the U.S. If approved, Moximed could achieve significant market penetration in the $5 billion+ knee OA treatment space. However, as a private company, financial details and timeline to profitability remain undisclosed. The success of the MISHA system hinges on positive clinical data, FDA approval, and widespread payer coverage.

Upcoming Catalysts (preview)

• Q3 2026FDA Decision on MISHA Knee System Premarket Approval70% success
• Q2 2026Publication of Pivotal Trial 2-Year Follow-Up Results80% success
• Q4 2026CMS Reimbursement Decision for Implantable Knee Unloader60% success